Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Thiazolidinedione. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thiazolidinedione SCHEMBL135101 | 0.97 | — | — | |
| Thiazolidinedione SCHEMBL4828229 | 0.97 | GSK3A (1.00) | — | |
| Thiazolidinedione SCHEMBL5043 | 0.97 | — | — | |
| Thiazolidinedione SCHEMBL4895522 | 0.97 | — | — | |
| Thiazolidinedione SCHEMBL6789129 | 0.94 | — | — | |
| Thiazolidinedione SCHEMBL5795315 | 0.94 | — | — | |
| Thiazolidinedione SCHEMBL7844590 | 0.94 | — | — | |
| Thiazolidinedione SCHEMBL3294959 | 0.94 | — | — | |
| Thiazolidinedione SCHEMBL8522420 | 0.92 | — | — | |
| Thiazolidinedione SCHEMBL5467719 | 0.85 | GSK3A (0.76) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4404929-A2 | INHIBITORS OF THE MTDH-SND1 PROTEIN COMPLEX FOR CANCER THERAPY | The Trustees of Princeton University (US) | 2024-07-31 | — | — | EP | claimed |
| WO-2023064669-A2 | INHIBITORS OF THE MTDH-SND1 PROTEIN COMPLEX FOR CANCER THERAPY | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2023-04-20 | — | — | WO | claimed |
| CN-112512524-A | Method of administering a therapeutically effective amount of 5- [ [4- [2- [5- (1-hydroxyethyl) pyridin-2-yl ] ethoxy ] phenyl ] methyl ] -1, 3-thiazolidine-2, 4-dione | 米尼奥尔克斯治疗有限公司 | 2021-03-16 | — | — | CN | claimed |
| WO-2024258316-A1 | NOVEL POTENTIAL ANTIFUNGAL AGENTS BASED ON THIAZOLIDINE-2,4-DIONE AND A TRIAZOLE | Общество с ограниченной ответственностью "Л-Био" | 2024-12-19 | — | — | WO | disclosed |
| EP-3500260-B1 | GLITAZONES FOR TOPICAL APPLICATION | SUGARMAN JEFFREY L (US) | 2024-08-14 | — | — | EP | disclosed |
| EP-4404929-A2 | INHIBITORS OF THE MTDH-SND1 PROTEIN COMPLEX FOR CANCER THERAPY | The Trustees of Princeton University (US) | 2024-07-31 | — | — | EP | disclosed |
| WO-2023064669-A2 | INHIBITORS OF THE MTDH-SND1 PROTEIN COMPLEX FOR CANCER THERAPY | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2023-04-20 | — | — | WO | disclosed |
| US-11390868-B2 | Treatment of filaggrin (FLG) related diseases by modulation of FLG expression and activity | CURNA, INC. (US) | 2022-07-19 | — | — | US | disclosed |
| CN-112823004-A | Use of 5- [ [4- [2- [ 5-acetylpyridin-2-yl ] ethoxy ] benzyl ] -1, 3-thiazolidine-2, 4-dione and salts thereof | 米尼奥尔克斯治疗有限公司 | 2021-05-18 | — | — | CN | disclosed |
| EP-3801516-A1 | METHOD OF ADMINISTERING A THERAPEUTICALLY EFFECTIVE AMOUNT OF 5-[[4-[2-[5-(1-HYDROXYETHYL)PYRIDIN-2-YL]ETHOXY]PHENYL]METHYL]-1,3-THIAZOLIDINE-2,4-DIONE | Minoryx Therapeutics S.L. (ES) | 2021-04-14 | — | — | EP | disclosed |
| CN-112512524-A | Method of administering a therapeutically effective amount of 5- [ [4- [2- [5- (1-hydroxyethyl) pyridin-2-yl ] ethoxy ] phenyl ] methyl ] -1, 3-thiazolidine-2, 4-dione | 米尼奥尔克斯治疗有限公司 | 2021-03-16 | — | — | CN | disclosed |
| CN-101242829-B | Pharmaceutical composition comprising PPAR regulator | SANKYO CO | 2011-05-18 | — | — | CN | disclosed |
| WO-2010147768-A1 | PHARMACEUTICAL COMPOSITIONS OF COMBINATIONS OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS WITH PIOGLITAZONE | MERCK SHARP & DOHME CORP. (US) | 2010-12-23 | — | — | WO | disclosed |
| CN-101080246-A | Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use | ANGIOTECH INT AG (CH) | 2007-11-28 | — | — | CN | disclosed |
| US-20070060649-A1 | NOVEL LYSINE SALTS OF 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACID DERIVATIVES | CYMABAY THERAPEUTICS, INC. | 2007-03-15 | — | — | US | disclosed |
| CN-1882524-A | 4- ((phenoxyalkyl) thio) -phenoxyacetic acids and analogs | JANSSEN PHARMACEUTICA NV (BE) | 2006-12-20 | — | — | CN | disclosed |
| US-6706746-B2 | THIADIAZOLIDIN-2,4-DIONE COMPOUND | SANKYO COMPANY, LIMITED (JP) | 2004-03-16 | — | — | US | disclosed |
| CN-1056840-C | Oxime derivatives, their preparation and their therapeutic use | SANKYO CO (JP) | 2000-09-27 | — | — | CN | disclosed |
| CN-1167111-A | Thiazolidinedione derivatives, method for preparing derivatives and pharmaceutical compositions containing same | SENGA PHARMACEUTICAL LAB INC (JP) | 1997-12-10 | — | — | CN | disclosed |
| CN-1143639-A | Oxime derivatives, their preparation and their therapeutic use | SANKYO CO (JP) | 1997-02-26 | — | — | CN | disclosed |